# A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

> **NCT06924320** · PHASE1,PHASE2 · RECRUITING · sponsor: **Metsera, a wholly owned subsidiary of Pfizer** · enrollment: 132 (estimated)

## Conditions studied

- Obesity and Obesity-related Medical Conditions

## Interventions

- **DRUG:** MET233 and MET097
- **DRUG:** Placebo
- **DRUG:** MET233

## Key facts

- **NCT ID:** NCT06924320
- **Lead sponsor:** Metsera, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-03
- **Primary completion:** 2027-01-25
- **Final completion:** 2027-03-15
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06924320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06924320, "A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06924320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*